OncLive TV

Dr. Shaji Kumar on Upfront Combination Treatments in Multiple Myeloma

August 16th 2016

​Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the impact of combination treatments upfront in multiple myeloma.

Dr. Fishman Discusses Available Agents to Treat Patients With RCC

August 16th 2016

Mayer Fishman, MD, PhD, medical oncologist, Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, professor, Department of Oncologic Sciences and of Internal Medicine, University of South Florida Morsani College of Medicine, discusses the available agents to treat patients with renal cell carcinoma.

Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL

August 12th 2016

Dr. Michele Cavo on ASCT Role in Novel-Agent Era of Multiple Myeloma

August 12th 2016

Michele Cavo, MD, professor, Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses the role of upfront autologous stem cell transplantation (ASCT) in multiple myeloma.

Dr. Pecora on How the OCM Will Transform Operations For His Physician Group

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Dr. Pecora on Patient Management Payments Under the OCM

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Oncology Care Model (OCM) and other aspects of healthcare reform.

Dr. Pecora on How MACRA Needs Fine Tuning

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, talked about the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) and other aspects of healthcare reform.

Dr. Pecora on the Medicare Part B Drug Payment Model

August 12th 2016

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the Medicare Part B Drug Payment Model (OCM) and other aspects of healthcare reform.

Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC

August 11th 2016

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Dang on Neratinib in Patients With HER2-Positive Breast Cancer

August 11th 2016

Chau Dang, MD, medical oncologist, chief, West Harrison Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential of neratinib as a combination treatment for patients with HER2-positive breast cancer.

Dr. Filippo Pietrantonio on Using Nomogram for Patient Selection in CRC Trials

August 11th 2016

Dr. Susan O'Brien Compares Ibrutinib With Chemoimmunotherapy in Frontline CLL

August 11th 2016

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Dr. Reinhard Dummer on Toxicities with Binimetinib in Metastatic Melanoma

August 11th 2016

Dr. Michael L. Blute on Partial Nephrectomy Rates in RCC

August 10th 2016

Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer

August 10th 2016

Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

Dr. Dixon on Prevalence and Risk Factors of Male Breast Cancer

August 10th 2016

J. Michael Dixon, MD, professor of Surgery, consultant surgeon, and clinical director of the Breakthrough Breast Cancer Research Unit at the University of Edinburgh in Scotland, discusses the prevalence of and risk factors for breast cancer in males.

Dr. Frankie Ann Holmes on Duel Anti-HER2-Directed Therapy in Breast Cancer

August 10th 2016

Dr. Leslie Randall Discusses Evidence Supporting BRCA Testing in Ovarian Cancer

August 10th 2016

Leslie M. Randall, MD, associate professor of Gynecology/ Oncology, University of California Irvine, discusses evidence supporting the use of BRCA testing for patients with ovarian cancer.

Dr. Jonathan Trent on Pembrolizumab in Advanced Sarcomas

August 9th 2016

Dr. Arteaga on Ongoing Trials in Metastatic Breast Cancer

August 9th 2016

Carlos L. Arteaga, MD, associate director for Clinical Research, director, Center for Cancer Targeted Therapies, Vanderbilt-Ingram Cancer Center, discusses some of the ongoing trials exploring treatments for patients with metastatic breast cancer.